Functional effects of renal artery stent placement on treated and contralateral kidneys  by Leertouwer, Trude C. et al.
Kidney International, Vol. 62 (2002), pp. 574–579
Functional effects of renal artery stent placement on treated
and contralateral kidneys
TRUDE C. LEERTOUWER, FRANS H.M. DERKX, PETER M.T. PATTYNAMA, JAAP DEINUM,
LUKAS C. VAN DIJK, and MAARTEN A.D.H. SCHALEKAMP
Departments of Radiology and Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
Functional effects of renal artery stent placement on treated symptomatic renal artery stenosis is thought to be bene-
and contralateral kidneys. ficial by improving the function of the affected kidney
Background. This study examined the effects of stent place- or, at least, halting the progressive loss of renal function.ment for renal artery stenosis on the function of treated and
Revascularization by stent placement is now well ac-contralateral kidneys.
cepted as part of the treatment of atherosclerotic renalMethods. Eighteen patients who underwent stent placement
for unilateral renal artery stenosis presenting with hypertension artery stenosis.
and/or renal failure were studied before angiography and stent To date, clinical studies have failed to show the superi-
placement and at their one-year follow-up. Renal vein blood ority of either balloon angioplasty over medical therapysamples were taken at both sides, at each side simultaneously
[1], or stent placement over balloon angioplasty [2] withwith a sample from the aorta, to measure the plasma renin concen-
regard to blood pressure and renal function outcome.tration and the concentrations of 131I-hippuran and 125I-thalamate
during constant systemic infusion of these radiochemicals. This These studies, however, did not report hard data on the
allowed an assessment of the single-kidney contributions to the physiological effects of stent placement on renal func-
total renin secretion, effective renal plasma flow (131I-hippuran tion, especially of the treated kidney. Such data are re-clearance) and glomerular filtration rate (125I-thalamate clear-
quired to properly evaluate the value of renal arteryance).
stent placement, but are scarce due to the difficulty ofResults. At the one-year follow-up, the vein-to-artery renin
ratio at the treated side had decreased to normal, from 1.65  evaluating the function of the left and right kidneys sepa-
0.131 to 1.23  0.076 (mean  SEM; P  0.011), indicating rately.
an improved renal blood flow. Contralaterally it rose from The aim of this study, therefore, was to determine the1.09  0.042 to 1.17  0.029 (P  0.055) at follow-up. The
separate effects of renal artery stent placement on theextraction ratio of 131I-hippuran improved at the treated side
treated and untreated contralateral kidney rather than(0.48  0.049 to 0.62  0.034; P  0.003) and contralaterally
(0.67  0.033 to 0.73  0.026; P  0.043). The extraction ratio on the overall renal function. For this purpose, we deter-
of 125I-thalamate, which equals filtration fraction, improved at mined the single-kidney vein-to-artery ratios of renin
both sides (0.12  0.014 to 0.17  0.012 at the treated side, and extraction ratios of 131I-hippuran and 125I-thalamateP  0.001; 0.18  0.013 to 0.22  0.011 contralaterally, P 
prior to stent placement and at one-year follow-up in0.002). Two-kidney effective renal blood flow and glomerular
conjunction with measurements of the two-kidney clear-filtration rate remained unchanged.
Conclusion. Renal artery stenting was capable of causing ances of 131I-hippuran (effective renal plasma flow) and
improvement of glomerular filtration rate of the treated kidney, 125I-thalamate (glomerular filtration rate).
although the overall glomerular filtration rate did not change.
METHODS
Renal artery stenosis due to atherosclerosis is a pro- Patients
gressive disease that may ultimately lead to renal artery The study group comprised 18 patients (12 males, 6
occlusion and loss of renal function. Revascularization of females; aged 56  10.7 years; mean  SD) who under-
went stent placement for angiographically-proven symp-
tomatic unilateral atherosclerotic renal artery stenosisKey words: unilateral renal artery stenosis, artery occlusion, obstruc-
tion, stents and prostheses, angiography, glomerular filtration rate. of 50% luminal diameter reduction, and were studied
by means of renal vein blood sampling. These patientsReceived for publication January 8, 2001
were selected from a group of 40 consecutive patientsand in revised form February 6, 2002
Accepted for publication March 12, 2002 undergoing stent placement who were referred to our
hospital in the years 1997 and 1998. The length of the 2002 by the International Society of Nephrology
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treated kidney, as determined by ultrasound, was 8 in renal vein. The total clearances of hippuran and thala-
cm in all patients (10  0.3 cm; mean  SEM). Renal mate were taken as a measure of total effective renal
scintigraphy with mercaptoacetythiglycine (MAG3) and plasma flow (ERPF) and glomerular filtration rate (GFR),
other single-kidney renal function studies were per- respectively. The concentration of active renin in plasma
formed within one month before stent placement. These was measured by radioimmunoassay [4]. The normal
tests were repeated one year after the procedure, prior value of the vein-to-artery ratio of renin is 1.24. In case
to the angiographic follow-up examination. Medication of renal artery stenosis, the vein-to-artery ratio at the
regimen and blood pressure were recorded before the treated side is considered elevated with values 1.48.
intervention and at the follow-up examination. The study Contralateral suppression of renin secretion is defined
protocol was approved by the Local Committee of Hu- as a vein-to-artery renin ratio 1.13 [5].
man Research and written informed consent was ob-
tained from all patients. Stent placement
Pre-intervention digital subtraction angiograms wereRenal scintigraphy
obtained using aortic-flush injections. The stenosis was
Scintigraphy was performed with the patient in the
then crossed with a 5 F selective catheter and the lesion
supine position and using the posterior view. Patients
was predilated with an angioplasty balloon. A Palmazreceived 25 or 50 mg of captopril orally at one hour
stent (Johnson & Johnson Interventional Systems, Newbefore the examination. After intravenous administra-
York, NY, USA) was placed, and the procedure wastion of 74 MBq 99mTc-MAG3, data were collected in 10-
considered technically successful when both intravascu-second frames during a 20-minute period. The number
lar ultrasound and angiography showed complete stent-of total counts accumulated in the kidney during the first
vessel wall apposition, complete lesion-covering, and60 seconds was quantified and taken as a measure of
20% residual diameter stenosis [6]. If necessary, addi-the renal plasma flow to the affected and contralateral
tional stent dilation was performed. During the proce-kidneys. This method is based on the assumption that
dure the patients received 5000 IU of heparin, and hepa-the early part of the time-activity curve is determined
rin infusion was continued for 48 hours (20,000 to 30,000solely by the renal plasma flow. To avoid mentioning
IU per day). Oral acetylsalicylic acid (100 mg daily) wasabsolute data on renal blood flow, the ratio between the
started at the day of the procedure and continued duringcounts of the affected and the contralateral kidney was
the entire follow-up period.calculated. To avoid interference of the oral captopril
with subsequent tests used in this study to evaluate renal
Calculationsfunction, these tests were performed several days apart.
Two-kidney ERPF was calculated by dividing the infu-
Renal vein blood sampling sion rates of 131I-hippuran by the peripheral venous plasma
Concentrations of active renin and 131I-hippuran and concentration of 131I-hippuran. Similarly, two-kidney GFR
125I-thalamate in the left and right renal veins were mea- was calculated by dividing the infusion rate of 125I-thala-
sured and assayed as described by Wenting et al [3]. The mate by the peripheral venous plasma concentration of
method involves constant infusion of 131I-hippuran and 125I-thalamate. In addition, single-kidney RPF, ERPF and
125I-thalamate through an antecubital vein. In order to test GFR were calculated by using single-kidney data derived
whether the steady state was reached, blood samples were from MAG3 scintigraphy, as explained in the Appendix.
taken 60, 90 and 105 minutes after starting infusion. The
steady state was reached whenever the plasma concen- Statistical analysis
trations of two blood samples were the same. After reach-
Because a normal distribution could not be assumed,
ing the steady state, a renal venous blood sample was
the effect of intervention on single-kidney function pa-taken at each side simultaneously with a sample from
rameters was analyzed using the non-parametric Wil-the abdominal aorta. Samples from these sites were also
coxon signed ranks test at P  0.05. Analysis was re-used for renin measurements. Additional blood samples
peated for the subgroup of patients (N  9) who usedwere taken at 15-minute intervals from a peripheral vein
the same medication both pre-stenting and after one year,to estimate the total (two-kidney) clearances of hippuran
to test whether differences in medication had influencedand thalamate. All blood samples were immediately cen-
the results. We also examined whether there was anytrifuged and measurements were made in plasma. Deter-
difference in clinical parameters between the 18 patientsmination of blood oxygen saturation served to assure that
studied and the excluded patients. Finally, using regres-blood samples were taken from the renal veins. Single-
sion analysis we assessed whether there was any relation-kidney extraction ratios of 131I-hippuran and 125I-thala-
ship between the measured functional parameters andmate were defined as (A  V)/A * 100%, where A is
the activity in the abdominal aorta and V is the activity the clinical data on blood pressure and renal function.
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Table 1. Overview of clinical data of each patient individually
Angiotensin I
Clinical data pre-study Clinical data follow-up % stenosis
No. M/F Ind SBP DBP DDD SCr SBP DBP DDD SCr Pre-study FU
1 F HT 181 / 112 3.1 66 154 / 92 3.7 63 60 10
2 M HT 151 / 100 3.3 72 133 / 82 2.0 76 80 30
3 M RF 128 / 80 2.8 123 158 / 90 2.0 137 90 30
4 M RF 185 / 103 0.7 112 136 / 80 0.7 106 90 50
5 M HT 168 / 95 3.9 95 136 / 73 2.2 98 95 50
6 M RF 156 / 78 1.8 193 143 / 79 2.5 121 90 50
7 F RF 162 / 84 3.7 122 153 / 70 1.7 98 80 90
8 M HT 142 / 105 3.0 95 121 / 87 1.3 97 70 10
9 M HT 185 / 110 1.9 127 116 / 82 0.0 91 80 30
10 M RF 191 / 98 3.7 142 151 / 82 2.2 150 90 40
11 F PR 157 / 91 2.8 54 149 / 90 1.0 66 70 10
12 M PR 142 / 82 1.6 82 140 / 82 0.0 87 70 20
13 F HT 180 / 95 6.3 42 163 / 86 7.3 62 50 10
14 M HT 178 / 101 2.8 84 153 / 92 2.3 77 90 40
15 M HT 160 / 98 3.3 60 143 / 86 1.7 61 80 10
16 M RF 178 / 93 3.5 150 153 / 75 4.3 189 80 20
17 M HT 191 / 104 2.2 97 129 / 74 0.7 93 80 10
18 F RF 228 / 82 3.0 154 201 / 73 2.0 138 50 20
Abbreviations are: Ind, indication; HT, hypertension; RF, renal function impairment; PR, preservation of renal mass; SBP, systolic blood pressure (mm Hg); DBP,
diastolic blood pressure (mm Hg); DDD, defined daily dose; SCr, serum creatinine (mol/L); FU, follow-up.
Table 2. Overview of single-kidney function data of each patient
Pre-study Follow-up
No. GFR ERPF Ehipaf Ethalaf V/Aaf Ehipcl Ethalcl V/Acl GFR ERPF Ehipaf Ethalaf V/Aaf Ehipcl Ethalcl V/Acl
1 110 434 0.55 0.20 1.18 0.75 0.26 1.08 117 459 0.69 0.21 1.28 0.76 0.24 1.22
2 106 416 0.60 0.15 1.99 0.74 0.21 0.96 105 441 0.62 0.13 0.86 0.76 0.21 1.18
3 62 326 0.53 0.11 1.08 0.67 0.13 1.04 68 288 0.53 0.16 1.07 0.55 0.17 0.98
4 67 272 0.27 0.07 1.41 0.34 0.10 1.69 62 237 0.42 0.08 1.03 0.72 0.20 1.05
5 100 401 0.47 0.13 2.49 0.83 0.22 0.96 94 394 0.57 0.15 1.63 0.85 0.24 1.29
6 36 217 0.79 0.17 2.05 0.74 0.16 1.12 36 172 0.70 0.22 1.16 0.77 0.23 1.20
7 33 165 0.66 0.20 1.21 0.78 0.21 0.96 36 153 0.81 0.22 2.42 0.70 0.23 1.12
8 62 249 0.37 0.10 1.05 0.68 0.13 0.99 87 314 0.58 0.15 0.89 0.60 0.13 1.04
9 85 297 0.60 0.01 2.26 0.51 0.07 1.06 108 451 0.76 0.23 1.51 0.78 0.24 1.49
10 60 292 0.24 0.05 1.58 0.76 0.22 1.21 49 251 0.57 0.15 1.26 0.85 0.24 1.05
11 117 451 0.75 0.19 1.00 0.72 0.22 0.88 94 366 0.80 0.22 1.28 0.82 0.26 1.04
12 84 340 0.32 0.02 1.45 0.76 0.11 1.03 77 294 0.38 0.16 1.03 0.78 0.33 1.15
13 108 438 0.72 0.21 2.12 0.78 0.20 0.95 117 444 0.72 0.22 1.42 0.76 0.22 1.26
14 84 321 0.20 0.08 1.91 0.73 0.27 0.98 112 470 0.47 0.10 1.10 0.79 0.25 1.17
15 122 478 0.65 0.17 2.93 0.55 0.16 1.04 127 471 0.75 0.23 1.32 0.69 0.20 1.38
16 37 208 0.50 0.08 1.29 0.40 0.09 1.07 37 160 0.42 0.10 1.02 0.44 0.13 1.10
17 102 343 0.37 0.11 2.56 0.78 0.22 1.00 90 439 0.85 0.21 1.06 0.87 0.22 1.22
18 30 173 0.55 0.13 1.08 0.62 0.16 1.28 39 192 0.58 0.14 1.14 0.67 0.19 1.10
Abbreviations are: FU, follow-up; GFR, glomerular filtration rate; ERPF, effective renal plasma flow; Ehip, extraction ratio 131I-hippuran; Ethal, extraction ratio
125I-thalamate; af, affected; cl, contralateral; V/A, vein-to-artery renin ratio.
RESULTS distal main renal artery diameter) in 4 patients. (Results
of the patients with restenosis were also included in theOf the total group of 40 patients who underwent renal
analysis.) An overview of data of each patient individu-artery stent placement, 18 had complete recordings of
ally is given in Tables 1 and 2. Systolic blood pressuresingle-kidney functions before stent placement and at
decreased from 170 5.5 mm Hg (mean SEM) beforefollow-up. Of the 22 patients who were excluded, 4 had
stent placement to 146  4.4 mm Hg at follow-up. Dia-become dialysis dependent during the follow-up period,
stolic blood pressure decreased from 95  2.4 mm Hg4 had bilateral renal artery stenosis, and 4 refused follow-
to 82  1.6 mm Hg. The mean amount of antihyperten-up investigation. In the remaining 10 patients the clini-
sive drugs decreased from 2.9 0.28 DDDs before stentcian did not adhere to the protocol. Stent placement was
placement to 2.1 .40 DDDs at follow-up. Two patientsangiographically successful in all patients. Angiography
were cured from hypertension (normotensive withoutat follow-up (12 months in 16 patients and 6 months in
2 patients) showed restenosis 50% (compared to the medication).
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Table 3. Measured and calculated single-kidney function parameters obtained before stent placement and at one-year follow-up in 18 patients
Before stent placement At follow-up P value
Vein-to-artery renin ratio
Treated 1.650.131 1.230.076 0.011
Contralateral 1.090.042 1.170.029 0.055
Aortic renin concentration ng Ang I/(mL * h) 251114.0 9455.1 0.008
Extraction ratio 131I-hippuran
Treated 0.480.049 0.620.034 0.003
Contralateral 0.670.033 0.730.026 0.043
Extraction ratio of 125I-thalamate
Treated 0.120.014 0.170.012 0.001
Contralateral 0.180.013 0.220.011 0.002
Two-kidney ERPF mL/min 32323.1 33327.8 NS
Two-kidney GFR mL/min 767.2 777.8 NS
Flow ratio treated/contralateral 0.850.105 0.890.110 NS
RPF mL/min
Treated side 22624.5 21219.8 NS
Contralateral side 34233.2 28422.2 0.013
ERPF mL/min
Treated side 10615.6 13615.4 0.088
Contralateral side 22719.2 21319.4 0.039
GFR mL/min
Treated side 274.5 384.7 0.020
Contralateral side 597.1 646.4 NS
Values are mean  SEM. Abbreviations are: RPF, renal plasma flow; ERPF, effective renal plasma flow; GFR, glomerular filtration rate.
At follow-up, the renal vein-to-artery renin ratio at these calculations, is in agreement with the normalization
the treated side had decreased from 1.65  0.131 to of the renal vein-to-artery renin ratio of the treated kid-
normal, 1.23 0.076 (mean SEM; P 0.011; Table 3). ney. Calculated GFR of the treated side rose significantly
Contralaterally, the vein-to-artery renin ratio was 1.09 from 27  4.5 to 38  4.7 mL/min (P  0.020) and did
0.042 before stenting and 1.17  0.029 (P  0.055) at not change contralaterally (59  7.1 to 64  6.4 mL/
follow-up. Peripheral renin values decreased signifi- min; P  NS).
cantly from 251 114.0 ng angiotensin I/(mL * h) before The conclusions of the analysis in the subgroup of
stenting to 94  55.1 ng angiotensin I/(mL * h) at one- patients (N  9) with unchanged medication regimen
year follow-up (P  0.008). were consistent with those of the entire patient group.
The renal extraction ratios of 131I-hippuran improved It appeared that the 18 included patients had better base-
at the treated side (0.48  0.049 to 0.62  0.034; P  line renal function than excluded patients with a serum
0.003) and contralaterally (0.67  0.033 to 0.73  0.026; creatinine of 104 9.4 vs. 166 23.1mol/L (P 0.019).
P  0.043). The extraction ratio of 125I-thalamate, which There was no difference in clinical outcome between
equals the filtration fraction, improved at both sides patients who developed and those who did not develop
(0.12  0.014 to 0.17  0.012 at the treated side; P  restenosis. Finally, we found no relationship between
0.001; and 0.18  0.013 to 0.22  0.011 contralaterally, the parameters of kidney length and measured functional
respectively; P  0.002). The total (two-kidney) ERPF data with the (change of) clinical parameters in this study.
did not change (323  23.1 to 333  27.8 mL/min; P 
NS), and the same was true for the total effective renal
DISCUSSIONblood flow (575  45.6 to 564  66.7 mL/min; P  NS)
Evaluation of the effect of renal artery stent placementand total GFR (76  7.2 to 77  7.8 mL/min; P  NS).
on renal function is hampered by limited data on theThe calculated RPF value of the treated kidney was
function of the kidneys separately. In the present study226  24.5 mL/min before stent placement and 212 
single-kidney function was determined before and one19.8 mL/min at one-year follow-up (P  NS; Table 3).
year after renal artery stent placement.Calculated RPF of the contralateral kidney decreased
There was a decrease in the vein-to-artery renin ratiosignificantly from 342 33.2 to 284 22.3 mL/min (P
of the treated kidney and an increase contralaterally.0.013). The calculated ERPF of the treated kidney was
This finding extends previous studies on the effects of106  15.6 mL/min before stenting and 136  15.4 mL/
balloon angioplasty without stenting, which reportedmin at follow-up (P  0.088). The calculated ERPF of
that the lateralization of renin secretion to the stenosedthe contralateral kidney was 227  19.2 before stenting
kidney together with contralateral suppression had nor-and 213  19.4 mL/min at follow-up (P  0.039). The
flow improvement of the treated kidney, indicated by malized 6 to 39 months after the procedure [7, 8]. Under
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steady state conditions, an increased vein-to-artery renin GFR after stenting at the treated side. The total GFR
was unchanged, which may be explained by the fact thatratio of a kidney perfused by a stenosed renal artery is
a reflection of decreased renal blood flow rather than differences in function of the contralateral kidney coun-
terbalanced the beneficial effect on the treated kidney.increased renin secretion. Consequently, the normaliza-
tion of the vein-to-artery renin ratio observed in our Our finding that the filtration fraction of the contralateral
kidney was increased after stent placement, suggests astudy after one year primarily reflects a lasting increase
of blood flow to the treated kidney. We observed a de- proportionally larger decrease in RPF than in GFR. This
was in agreement with the calculated data of the contra-crease in aortic renin concentration, which indicates a
decrease of the two-kidney release of renin. Since the lateral kidney.
Although renal artery stent placement resulted in anrenin release of the contralateral kidney was suppressed
before the intervention, the observed change in arterial improvement of renal function in the patient group as
a whole, on an individual basis there was a wide rangerenin levels can be considered as evidence indicating a
decrease in renin release by the treated kidney. of responses. These may have been caused by restenosis
or by progressive renal disease. We found no significantData on single-kidney function measurements before
and after renal artery stent placement are, to the best of differences in single-kidney function data between the
patients with and without restenosis. Our analysis, how-our knowledge, not available in the literature. The present
study shows that the extraction ratios of 131I-hippuran and ever, was limited to a small group of patients.
The clinical management of renal artery stenosis re-125I-thalamate of the treated kidney improved at one-
year follow-up. Before intervention, the extraction ratio mains a controversial subject. Our group recently found
that there was no significant advantage of balloon angio-of 131I-hippuran was impaired, which is in accordance with
the literature [3]. This may be explained by a redistribution plasty over medical treatment for the treatment of renal
artery stenosis [1]. Concurrently, a randomized studyof renal blood flow in the presence of a renal artery steno-
sis in such a way that the sites where 131I-hippuran is comparing balloon angioplasty with stent placement for
renal artery stenosis found no differences in final clinicalexcreted by the tubules are bypassed. An alternative
explanation is a reduction in urine flow resulting in some outcome [2]. This might lead to the conclusion that there
is no place for revascularization of renal artery stenosis.tubular reabsorption of 131I-hippuran. The increase in
125I-thalamate extraction of the treated kidney reflects However, one should keep in mind that, especially in
the first study, there was crossover in almost one half ofan increase of filtration fraction and, probably, is due to
an increase in GFR. Remarkably, both the affected and the patients treated (that is, patients who were random-
ized for medical therapy were withdrawn from the studythe contralateral kidneys experienced an improvement
in function after renal artery stent placement. This was to undergo balloon angioplasty), which limits interpreta-
tion of the results. The present study was meant to inves-in accordance with data of Farmer et al, who performed
single-kidney GFR measurements using 51CrEDTA and tigate the pathophysiological effect of stent placement
on the function of the two kidneys separately. These99mTc scintigraphy [9]. The explanation of this finding is
at present unclear. data are lacking in the literature and were not supplied
by the mentioned randomized studies. The results of ourThus far, we have discussed our data in semiquantita-
tive terms. In order to obtain quantitative information, study show that renal artery stent placement leads to a
slight, but statistically significant improvement of single-we used calculations of single-kidney RPF, ERPF and
GFR on the basis of the flow ratio (treated/contralateral kidney function. This study, however, may be biased in
that the included patients had a better baseline renalkidney) as derived from the MAG3 time-activity curve.
The implicit assumption was that the extraction ratios function than the excluded patients. Yet, with regards
to the current trend in the literature toward expressingof the intravenously infused radiofarmacon were not dif-
ferent between the treated and contralateral kidney. Our the effect of revascularization in terms of stabilizing
rather than improving renal function, the results of ourstudy, however, shows that the extraction ratio of 131I-
hippuran at the treated side was smaller than the contra- present study should at least be considered to be positive.
Further studies should be performed to elucidate thelateral side. Therefore, our calculated data underesti-
mated the true renal plasma flow of the treated kidney subgroup of patients who may clinically benefit from the
intervention.and, consequently, the GFR of the treated kidney. It
should be noted that MAG3-scintigraphy was performed Some limitations of the present study should be ad-
dressed. First, the study group was small, which limitswith a captopril challenge, which is known to reduce the
extraction ratio of 131I-hippuran [3]. The direction of extrapolation of the results. Further studies with larger
patient groups are mandatory to confirm our findings.changes as shown by our calculations, however, is in agree-
ment with the conclusions derived from the renin mea- Second, serial single-kidney measurements were avail-
able in only 18 of the 40 patients. This may have causedsurements.
The two sets of data showed an increase of ERPF and a selection bias, because, as mentioned earlier, included
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ERPFtr/ERPFcl  (Ehiptr/Ehipcl)patients had a somewhat lower serum creatinine at base-
* (Flowcountstr/Flowcountscl) (Eq. 6)line than the excluded patients. Third, as explained ear-
lier in this article, the renal blood flow measurements Total effective renal plasma flow is defined as:
derived from MAG3-scintigraphy should be interpreted ERPFtr  ERPFcl  total C-hip (Eq. 7)
with caution. Fourth, the single-kidney measurements in which C-hip  total clearance of 131I-hippuran.
From equations 1, 2, 5, 6 and 7 it follows that:may have been influenced by the medication used at the
RPFtr  Flowcountstr * total C-hip/(Ehiptrtime of renal vein blood sampling. This, however, seems
less likely since the conclusions derived from the analysis * Flowcountstr)  (Ehipcl * Flowcountscl) (Eq. 8)
in patients with unchanged medication were consistent RPFcl  Flowcountscl * total C-hip/(Ehiptr
with those derived from the entire patient group.
* Flowcountstr)  (Ehipcl * Flowcountscl) (Eq. 9)
In conclusion, renal artery stent placement is capable
From equations 1, 2, 8 and 9 it follows that:
of causing a slight improvement of glomerular filtration
ERPFtr  Flowcountstr * Ehiptr * total C-hip/(Ehiptrrate of the treated kidney, although the overall glomeru-
* Flowcountstr)  (Ehipcl * Flowcountscl) (Eq. 10)lar filtration rate did not change.
ERPFcl  Flowcountscl * Ehipcl * total C-hip/(Ehiptr
Reprint requests to Trude C. Leertouwer, M.D., Department of Radi- * Flowcountstr)  (Ehipcl * Flowcountscl) (Eq. 11)ology, University Hospital Rotterdam, Dr. Molewaterplein 40, 3015 GD
From equations 3, 4, 8 and 9, it follows that:Rotterdam, the Netherlands.
E-mail: pattynama@rond.azr.nl GFRtr  Flowcountstr * Ethaltr * total C-hip/(Ehiptr
* Flowcountstr)  (Ehipcl * Flowcountscl) (Eq. 12)
GFRcl  Flowcountscl * Ethalcl * total C-hip/(EhiptrAPPENDIX
* Flowcountstr)  (Ehipcl * Flowcountscl) (Eq. 13)The renal plasma flow of the treated side (RPFtr) and contralaterally
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